Arrowstreet Capital
OTLK icon

Arrowstreet Capital’s Outlook Therapeutics OTLK Stock Holding History

Arrowstreet Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,365
Closed -$35K – 2449
2020
Q4 		$35K Sell
1,365
-1,165
-46% -$24.3K ﹤0.01% 2243
2020
Q3 		$36K Buy
+2,530
New +$56.4K ﹤0.01% 2288

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Arrowstreet Capital's OTLK Position: Q1 2021 in Review

Arrowstreet Capital sold out of Outlook Therapeutics (OTLK) in Q1 2021, closing a stake of 1,365 shares — an estimated $35K sold.

Arrowstreet Capital first reported a position in OTLK in Q3 2020 and held it in 2 quarters. The position peaked at $36K in Q3 2020. 49 funds tracked by Wall St. Rank hold OTLK as of Q1 2021.

  • Arrowstreet Capital reported no remaining Outlook Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 1,365 Outlook Therapeutics shares in Q1 2021, an estimated $35K.
  • Arrowstreet Capital first reported a position in Outlook Therapeutics in Q3 2020 and held it in 2 quarters.
  • Arrowstreet Capital's Outlook Therapeutics position peaked at $36K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.